[Evidence-based therapy for chronic leukemia]

Nihon Naika Gakkai Zasshi. 2003 Jun 10;92(6):979-85.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Clinical Trials as Topic
  • Enzyme Inhibitors / therapeutic use
  • Evidence-Based Medicine*
  • Fusion Proteins, bcr-abl
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use
  • Rituximab
  • Transplantation, Homologous
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Alemtuzumab
  • Rituximab
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Vidarabine
  • fludarabine